Nitinol Medical Technologies' CardioSEAL
This article was originally published in The Gray Sheet
Transcatheter Occlusion of Patent Foramen Ovale in Stroke Registry, announced July 27, will allow physicians worldwide to pool data on PFO closure and to support the use of the minimally invasive septal occulsion system. Nitinol is beginning a 15-center PFO trial of CardioSEAL in the U.S. and Canada
You may also be interested in...
Novartis has long championed the idea of making Sandoz an autonomous unit within the Swiss originator while stopping short of carving out the business altogether. Rumors continue to swirl around a potential deal, which was discussed during the recent virtual Meet Novartis Management event.
Health technology assessment body says that while iRhythm Technologies’ Zio XT service improves cardiac arrhythmia detection, more data must be collected to address evidence gaps about its benefit.
UK start-up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country. See what Iceni’s CEO Rob Field said about it here.